Cargando…

Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide

INTRODUCTION: Limited data are available on the relationship between quality of life (QoL) change and significant degrees of reduction in glycated haemoglobin (HbA1c) and/or weight loss in people with type 2 diabetes (T2D). We explored the associations between HbA1c targets and/or weight loss achiev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boye, Kristina S., Sapin, Hélène, Dong, Wenxiu, Williamson, Suzanne, Lee, Clare J., Thieu, Vivian Thuyanh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570229/ https://www.ncbi.nlm.nih.gov/pubmed/37668888 http://dx.doi.org/10.1007/s13300-023-01457-7

Ejemplares similares

Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme
por: Boye, Kristina S., et al.
Publicado: (2023)

OR03-1 Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program
por: Allen, Sheryl Elaine, et al.
Publicado: (2022)

The Benefits of Safely Achieving Near Normoglycemia from the Perspective of People with Type 2 Diabetes: A Quantitative Survey Study
por: Gelhorn, Heather L, et al.
Publicado: (2022)

The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective
por: Gelhorn, Heather, et al.
Publicado: (2021)

Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
por: Lee, Clare J, et al.
Publicado: (2023)

Estimating meaningful change for The Impact of Weight on Self-Perception (IW-SP) questionnaire among people with type 2 diabetes
por: Gelhorn, Heather L., et al.
Publicado: (2023)

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1
por: Srinath, Reshmi, et al.
Publicado: (2023)

Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes
por: Matza, Louis S., et al.
Publicado: (2022)

Weight loss efficiency and safety of tirzepatide: A Systematic review
por: Lin, Fei, et al.
Publicado: (2023)

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
por: Nauck, Michael A., et al.
Publicado: (2022)

Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
por: Viljoen, Adie, et al.
Publicado: (2023)

Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review
por: Boye, Kristina S, et al.
Publicado: (2022)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison
por: Vadher, Karan, et al.
Publicado: (2022)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis
por: Boye, Kristina S., et al.
Publicado: (2022)

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
por: Heise, Tim, et al.
Publicado: (2023)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

THU255 Tirzepatide-induced Weight Loss In A Type 2 Diabetic Taking Oral Contraceptives
por: Arunachalam, Amar, et al.
Publicado: (2023)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
por: Anala, Alekya Devi, et al.
Publicado: (2023)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study
por: Poon, Jiat Ling, et al.
Publicado: (2023)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
por: Sinha, Rachel, et al.
Publicado: (2023)

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
por: De Block, Christophe, et al.
Publicado: (2022)

Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
por: Dutta, Palak, et al.
Publicado: (2023)

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023)

The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study
por: Boye, Kristina S., et al.
Publicado: (2022)

Managing post stroke hyperglycaemia: moderate glycaemic control is better? An update
por: Wan Sulaiman, Wan Aliaa, et al.
Publicado: (2014)

Factors associated with glycaemic control in Singapore children and young people with diabetes
por: Lek, Ngee, et al.
Publicado: (2013)

Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012–2019
por: Boye, Kristina S., et al.
Publicado: (2021)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
por: le Roux, Carel W., et al.
Publicado: (2022)

Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
por: Karrar, Hani Raka, et al.
Publicado: (2023)

Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
por: Blüher, Matthias, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6gp3h6jd0taebt42qgcv3mmj75